Latest News and Press Releases

CTIM-76 Phase 1 clinical trial to focus on CLDN6-positive gynecologic and testicular cancers Company expects to enroll first patient in mid-2024 PHILADELPHIA, May 02, 2024 (GLOBE NEWSWIRE) --...

Financing includes new and existing leading healthcare investors Proceeds, along with existing cash and cash equivalents, are expected to extend cash runway into 2028 PHILADELPHIA, May 02, 2024 ...

PHILADELPHIA, April 01, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today...

CTIM-76 IND filing on track for late March 2024 Cash and cash equivalents of $14.4 million as of December 31, 2023 Company expects its cash and cash equivalents will continue to fund operations into...

CTIM-76 IND filing on track for late Q1 2024 Cash and cash equivalents of $21.7 million as of September 30, 2023 Company expects its cash and cash equivalents will continue to fund operations into...

CTIM-76 exhibits dose-proportional tumor responses and safety in preclinical models Benchmarking studies comparing CTIM-76 with clinical-stage CLDN6 therapies support CTIM-76's differentiated product...

PHILADELPHIA, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today...

Company expects its cash and cash equivalents will continue to fund operations into late 2024 Cash and cash equivalents of $25.1 million as of June 30, 2023 CTIM-76 IND filing on track for...

PHILADELPHIA, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company dedicated to improving the lives of patients living...

CTIM-76 IND filing on track for Q1 2024 Preclinical data on CLDN6 bispecific antibody CTIM-76 presented at AACR Annual Meeting 2023 Cash and cash equivalents of $29.8 million as of March 31,...